Goldman Sachs employees named as suspects in Brazil fraud probe

Two Goldman Sachs employees have been formally indicted by São Paulo civil police in connection with an alleged fraud scheme involving Oncoclinicas do Brasil Serviços Médicos, one of Brazil’s largest cancer-treatment companies. The probe centers on whether the pair helped obscure the true ownership structure of the firm to avoid triggering a costly mandatory buyout of minority shareholders. The employees, Felipe Guerra Acosta and Natan Lima Reinig, are accused of misrepresenting ownership stakes held through a series of investment vehicles known as Josephina I, II, and later Josephina III. If the allegations hold up, the maneuver allowed major shareholders to quietly breach a critical ownership threshold without facing the consequences baked into the company’s own bylaws. The poison pill problem At the heart of the case is a corporate governance mechanism that many public companies use to protect minority investors. Oncoclinicas’ bylaws include a “poison pill” provision, a rule designed to prevent any single party from amassing too much control without compensating other shareholders. In this case, the trigger point was 15% ownership. Cross that line, and the controlling party woul...